Diaceutics (DXRX) Share Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DXRX shares.
View DXRX analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month price targets for Diaceutics' stock. Their DXRX share price forecasts range from GBX 150 to GBX 150. On average, they predict the company's share price to reach GBX 150 in the next year. This suggests a possible upside of 42.9% from the stock's current price.
View analysts price targets for DXRX or view top-rated stocks among Wall Street analysts.

Diaceutics' stock was trading at GBX 75.50 at the beginning of the year. Since then, DXRX stock has increased by 39.1% and is now trading at GBX 105.
View the best growth stocks for 2023 here.

Diaceutics trades on the London Stock Exchange (LON) under the ticker symbol "DXRX."

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of DXRX stock can currently be purchased for approximately GBX 105.

Diaceutics (LON:DXRX) has a market capitalization of £88.69 million and generates £21.90 million in revenue each year.

The company employs 151 workers across the globe.